C. Lewanski

6.5k total citations · 1 hit paper
41 papers, 3.0k citations indexed

About

C. Lewanski is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, C. Lewanski has authored 41 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in C. Lewanski's work include Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (15 papers) and Cancer Immunotherapy and Biomarkers (13 papers). C. Lewanski is often cited by papers focused on Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Research Studies (15 papers) and Cancer Immunotherapy and Biomarkers (13 papers). C. Lewanski collaborates with scholars based in United Kingdom, United States and Spain. C. Lewanski's co-authors include Á. Artal, Achim Rittmeyer, Julien Mazières, Keunchil Park, Johan Vansteenkiste, Daniel Waterkamp, Marcin Kowanetz, Pei He, Louis Fehrenbacher and Jing Yi and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

C. Lewanski

39 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

2016 2.1k citations Louis Fehrenbacher, Alexander I. Spira et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Lewanski United Kingdom	16	2.4k	1.7k	587	389	354	41	3.0k
Shelley Coleman United States	7	2.8k 1.1×	1.9k 1.2×	599 1.0×	387 1.0×	399 1.1×	10	3.2k
Michael McCleod United States	17	2.5k 1.0×	1.7k 1.0×	341 0.6×	276 0.7×	410 1.2×	44	3.0k
Alexander I. Spira United States	10	2.2k 0.9×	1.3k 0.8×	636 1.1×	384 1.0×	228 0.6×	19	2.5k
Maen Hussein United States	15	2.5k 1.0×	1.7k 1.0×	642 1.1×	224 0.6×	249 0.7×	46	2.9k
S. Cedrés Spain	20	1.3k 0.6×	1.2k 0.7×	305 0.5×	272 0.7×	363 1.0×	80	2.2k
Daniel Waterkamp United States	21	3.5k 1.4×	1.9k 1.1×	813 1.4×	530 1.4×	311 0.9×	39	3.9k
Ryan D. Gentzler United States	20	2.1k 0.8×	1.4k 0.8×	426 0.7×	219 0.6×	285 0.8×	86	2.5k
Virginia Ferraresi Italy	25	1.3k 0.5×	1.0k 0.6×	370 0.6×	247 0.6×	635 1.8×	125	2.4k
W. Scott Webster United States	17	1.9k 0.8×	1.3k 0.8×	1.1k 1.9×	403 1.0×	673 1.9×	23	2.8k
Faith E. Nathan United States	23	1.4k 0.6×	1.2k 0.7×	291 0.5×	317 0.8×	356 1.0×	45	2.1k

Countries citing papers authored by C. Lewanski

Since Specialization

Citations

This map shows the geographic impact of C. Lewanski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Lewanski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Lewanski more than expected).

Fields of papers citing papers by C. Lewanski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Lewanski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Lewanski. The network helps show where C. Lewanski may publish in the future.

Co-authorship network of co-authors of C. Lewanski

This figure shows the co-authorship network connecting the top 25 collaborators of C. Lewanski. A scholar is included among the top collaborators of C. Lewanski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Lewanski. C. Lewanski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dubash, Suraiya, Marianna Inglese, Francesco Mauri, et al.. (2020). Spatial heterogeneity of radiolabeled choline positron emission tomography in tumors of patients with non-small cell lung cancer: first-in-patient evaluation of [¹⁸F]fluoromethyl-(1,2-²H₄)-choline. Theranostics. 10(19). 8677–8690. 12 indexed citations

Lee, Siow Ming, Sunil Upadhyay, C. Lewanski, et al.. (2019). The clinical role of VeriStrat testing in patients with advanced non–small cell lung cancer considered unfit for first-line platinum-based chemotherapy. European Journal of Cancer. 120. 86–96. 5 indexed citations

Califano, Raffaele, Rohit Lal, C. Lewanski, et al.. (2018). Patient Selection for Anti-PD-1/PD-L1 Therapy in Advanced Non-Small-Cell Lung Cancer: Implications for Clinical Practice. Future Oncology. 14(23). 2415–2431. 27 indexed citations

Dubash, Suraiya, Kathrin Heinzmann, Francesco Mauri, et al.. (2018). Clinical translation of [18F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 45(13). 2285–2299. 31 indexed citations

Mazières, Julien, C. Lewanski, Shirish M. Gadgeel, et al.. (2018). 136PD_PR 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR). Journal of Thoracic Oncology. 13(4). S79–S79. 16 indexed citations

Ferry, David, Lucinda Billingham, Hugh Jarrett, et al.. (2017). Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer. 83. 302–312. 15 indexed citations

Morgensztern, Daniel, Teng Jin Ong, Manuel Cobo, et al.. (2017). ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. v635–v636. 1 indexed citations

Popat, Sanjay, Laura Hughes, Mary O’Brien, et al.. (2017). P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial). Journal of Thoracic Oncology. 12(1). S1215–S1216. 3 indexed citations

Rittmeyer, Achim, David C. Smith, Johan Vansteenkiste, et al.. (2017). Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR). Pneumologie. 71(S 01). S1–S125. 4 indexed citations

10.

Pérol, M., Tudor–Eliade Ciuleanu, Rubén Dario Kowalyszyn, et al.. (2017). Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer. Lung Cancer. 112. 126–133. 13 indexed citations

11.

Artal, Á., Julien Mazières, Louis Fehrenbacher, et al.. (2017). Evaluation of non-classical response by immune-modified RECIST and efficacy of atezolizumab beyond disease progression in advanced NSCLC: Results from the randomized Phase II study POPLAR. Annals of Oncology. 28. ii35–ii35. 6 indexed citations

12.

Cree, Ian A., Richard Booton, Paul Cane, et al.. (2016). PD‐L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology. 69(2). 177–186. 65 indexed citations

13.

Fehrenbacher, Louis, Alexander I. Spira, Marcus Ballinger, et al.. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet. 387(10030). 1837–1846. 2112 indexed citations breakdown →

14.

Palmieri, Carlo, Iain R. Macpherson, Felipe Ades, et al.. (2015). Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer. Oncotarget. 7(11). 13209–13220. 4 indexed citations

15.

Lee, Siow Ming, C. Lewanski, Nicholas Counsell, et al.. (2014). Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases. JNCI Journal of the National Cancer Institute. 106(7). 98 indexed citations

16.

Lee, Siow Ming, Iftekhar Khan, Sunil Upadhyay, et al.. (2012). First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 13(11). 1161–1170. 133 indexed citations

17.

Anand, Girija, C. Lewanski, Steven Cowman, & James E. Jackson. (2010). Superior Vena Cava Stent Migration into the Pulmonary Artery Causing Fatal Pulmonary Infarction. CardioVascular and Interventional Radiology. 34(S2). 198–201. 11 indexed citations

18.

Keane, Margaret G., et al.. (2009). A rare complication of finger sepsis secondary to blood glucose monitoring. BMJ Case Reports. 2009. bcr0620092010–bcr0620092010. 1 indexed citations

19.

Lewanski, C. & William J. Gullick. (2001). Radiotherapy and cellular signalling. The Lancet Oncology. 2(6). 366–370. 55 indexed citations

20.

Botwood, N., C. Lewanski, & C. Lowdell. (1999). The risks of treating keloids with radiotherapy.. British Journal of Radiology. 72(864). 1222–1224. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact